0001683168-26-003530
SEC filingPre-revenue biotech with a licensing deal, but cash burn and reliance on CEO funding highlight high execution risk.
The company remains pre-revenue, with no product sales in 2025. It has entered into a global licensing agreement with NeuRX for BreastCheck, which provides a path to commercialization. However, revenue recognition will only begin upon commercial launch, which is subject to regulatory approvals and market adoption. The company's ability to generate future revenue is entirely dependent on the success of this partnership.
Operating losses continue, funded primarily through advances from the CEO and post-period debt and equity raises. The company has not yet achieved profitability and expects to incur further losses as it supports the licensing deal and pursues a Nasdaq listing. The reliance on external funding sources introduces liquidity risk.
The company is pursuing a listing on Nasdaq, which would provide access to capital markets. Advisory fees for this process are being paid in shares. The listing is pending and subject to regulatory approval.
CEO and directors have waived their salaries until the listing is completed. Post-listing, new service agreements will be established at market rates. This compensation structure aligns management incentives with the successful listing and long-term value creation.
The company's IP portfolio includes patents in the UK, US, and PCT filings covering thermochromic liquid crystal film technology for breast thermography and other applications. BreastCheck and FootFlow are registered as Class I medical devices in the US and EU, allowing over-the-counter sales without premarket approval. The company believes no direct competitors use similar technology, but the market for home-based thermography is unproven. The NeuRX agreement provides a path to commercialization, but any failure by the licensee to obtain regulatory approvals or achieve market adoption would severely impact the company's prospects.
The company's ability to continue as a going concern is dependent on securing additional financing and successfully commercializing its products through the NeuRX partnership. The lack of revenue and ongoing operating losses create substantial doubt about its ability to meet obligations over the next twelve months. Management's plans include the Nasdaq listing and further debt or equity financing, but there is no assurance these will be completed.